Hepatitis B oculta en pacientes VIH positivos de una institución de salud en Barranquilla Colombia

Article information

Resumen

Objetivo

Establecer la frecuencia de la infección por Hepatitis B en los pacientes VIH positivos atendidos en la IPS VitalSalud de Barranquilla, Colombia.

Métodos

Se realizó un perfil serológico para Hepatitis B en los pacientes VIH positivos, consistente en: HBs Ag, Anticore IgG. Estos exámenes se practicaron entre el mes de junio del 2007 hasta julio del 2009.

Resultados

En 24 meses se realizaron exámenes para la detección de Hepatitis B en 103 pacientes VIH positivos. Hubo una prevalencia del 3,1% (tres pacientes) con Hepatitis B crónica. Cuatro pacientes fallecieron durante el período del estudio, ninguno positivo para infección por Hepatitis B. Se detectaron 6 pacientes con Ig G core para VHB positivo aislado, es decir con sospecha de Hepatitis B oculta, la cual se confirmó solo en un paciente con carga viral para ADN de VHB positiva (158 copias/ml). Este paciente no se hallaba usando lamivudina en el momento del examen.

Conclusión

La prevalencia de Hepatitis B en nuestros pacientes corresponde a la reportada en todo el territorio nacional. La búsqueda de infección oculta por Virus de Hepatitis B en los pacientes VIH positivos asistentes a nuestra institución arrojó como resultado un solo paciente con esta patología y con una baja carga viral. La estrategia para el diagnóstico la infección oculta por VHB en los pacientes usando lamivudina debe ser más estudiada.

Palabras claves:

Hepatitis B

SIDA

Hepatitis B oculta

Abstract

Objective

The objective is to establish the frequency of Hepatitis B (VHB) co-infection in HIV outpatients at VitalSalud Health Center in Barranquilla, Colombia.

Methods

Two serological tests to diagnose Hepatitis B in our HIV patients were performed: Hepatitis B surface antigen and Anticore type Ig G (anti HBC Ig G). These tests were run between July, 2007 and July, 2009.

Results

The tests were applied to 103 HIV patients. There was a prevalence of 3.1% (3 patients) for chronic Hepatitis B. Four patients passed away during the study term, none of them was Hepatitis B positive. Six patients with isolated anti HBc Ig G were detected, and only one of them had a positive viral load for VHB DNA (158 copies/ml). This patient was not taking lamivudine at the time of the test.

Conclusions

The prevalence of VHB in our patients is similar to the prevalence reported in our country as a whole. The search for occult hepatitis B was positive, with a low viral load, in one out of 103 of our patients. The strategies for diagnosis of occult hepatitis B in HIV patients under lamivudine treatment require further research.

Key words:

Hepatitis B

HIV

AIDS

Occult Hepatitis B

Full text is only aviable in PDF

Referencias

[1.]

OMS. Hepatitis B. Organización Mundial de la Salud 2008 [updated 2008; cited Oct 2009]; Available from: http://www.who.int/mediacentre/factsheets/fs204/es/print.html.

[2.]

IDROVO CUBIDES Víctor, SUAREZ Q Carmen Yanette, ALVAREZ QUINTERO Patricia. Epidemiología e historia natural de la hepatitis B. Rev Col Gastroenterol. 2009; 24(suppl.1):4s-12s.

[3.]

W.J. Edmunds, G.F. Medley, D.J. Nokes, A.J. Hall, H.C. Whittle.

The influence of age on the development of the hepatitis B carrier state.

Proc Biol Sci, 253 (1993), pp. 197-201

http://dx.doi.org/10.1098/rspb.1993.0102 | Medline

[4.]

C.L. Thio, E.C. Seaberg, R. Skolasky Jr., J. Phair, B. Visscher, A. Munoz, et al.

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

Lancet, 360 (2002), pp. 1921-1926

Medline

[5.]

R. Weber, C.A. Sabin, N. Friis-Moller, P. Reiss, W.M. El-Sadr, O. Kirk, et al.

Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Arch Intern Med, 166 (2006 Aug 14-28), pp. 1632-1641

http://dx.doi.org/10.1001/archinte.166.15.1632 | Medline

[6.]

B.J. McMahon, W.L. Alward, D.B. Hall, W.L. Heyward, T.R. Bender, D.P. Francis, et al.

Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state.

J Infect Dis, 151 (1985), pp. 599-603

Medline

[7.]

S.C. Hadler, F.N. Judson, P.M. O’Malley, N.L. Altman, K. Penley, S. Buchbinder, et al.

Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection.

J Infect Dis, 163 (1991), pp. 454-459

Medline

[8.]

K.C. Hyams.

Risks of chronicity following acute hepatitis B virus infection: a review.

Clin Infect Dis, 20 (1995), pp. 992-1000

Medline

[9.]

L.B. Polish, C.N. Shapiro, F. Bauer, P. Klotz, P. Ginier, R.R. Roberto, et al.

Nosocomial transmission of hepatitis B virus associated with the use of a spring-loaded finger-stick device.

N Engl J Med, 326 (1992), pp. 721-725

http://dx.doi.org/10.1056/NEJM199203123261101 | Medline

[10.]

S.T. Goldstein, F. Zhou, S.C. Hadler, B.P. Bell, E.E. Mast, H.S. Margolis.

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

Int J Epidemiol, 34 (2005), pp. 1329-1339

http://dx.doi.org/10.1093/ije/dyi206 | Medline

[11.]

J.H. Hoofnagle, A.M. Di Bisceglie.

Serologic diagnosis of acute and chronic viral hepatitis.

Semin Liver Dis, 11 (1991), pp. 73-83

http://dx.doi.org/10.1055/s-2008-1040426 | Medline

[12.]

W.L. Alward, B.J. McMahon, D.B. Hall, W.L. Heyward, D.P. Francis, T.R. Bender.

The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma.

J Infect Dis, 151 (1985), pp. 604-609

Medline

[13.]

M. Hofer, H.I. Joller-Jemelka, P.J. Grob, R. Luthy, M. Opravil.

Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study.

Eur J Clin Microbiol Infect Dis, 17 (1998), pp. 6-13

Medline

[14.]

L. Piroth, C. Binquet, M. Vergne, A. Minello, C. Livry, J.B. Bour, et al.

The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients.

J Hepatol, 36 (2002), pp. 681-686

Medline

[15.]

M.J. Koziel, M.G. Peters.

Viral hepatitis in HIV infection.

N Engl J Med, 356 (2007), pp. 1445-1454

http://dx.doi.org/10.1056/NEJMra065142 | Medline

[16.]

E.A. Santos, C.F. Yoshida, V.C. Rolla, J.M. Mendes, I.F. Vieira, J. Arabe, et al.

Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1.

Eur J Clin Microbiol Infect Dis, 22 (2003), pp. 92-98

http://dx.doi.org/10.1007/s10096-002-0868-0 | Medline

[17.]

J.L. Dienstag, E.R. Schiff, T.L. Wright, R.P. Perrillo, H.W. Hann, Z. Goodman, et al.

Lamivudine as initial treatment for chronic hepatitis B in the United States.

N Engl J Med, 341 (1999), pp. 1256-1263

http://dx.doi.org/10.1056/NEJM199910213411702 | Medline

[18.]

Ramirez I, Cataño J. Prevalencia de Hepatitis B oculta en una cohorte prospectiva de pacientes con VIH Iatreia. 2008;21(suplemento 1).

[19.]

S. Ramia, J. Mokhbat, F. Ramlawi, M. El-Zaatari, B. Occult hepatitis.

Occult hepatitis B virus infection in HIV-infected Lebanese patients with isolated antibodies to hepatitis B core antigen.

Int J STD AIDS, 19 (2008), pp. 197-199

http://dx.doi.org/10.1258/ijsa.2007.007200 | Medline

[20.]

P. Miailhes, M.A. Trabaud, P. Pradat, B. Lebouche, M. Chevallier, P. Chevallier, et al.

Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.

Clin Infect Dis, 45 (2007), pp. 624-632

http://dx.doi.org/10.1086/520752 | Medline

[21.]

K. Pogany, H.L. Zaaijer, J.M. Prins, F.W. Wit, J.M. Lange, M.G. Beld.

Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients.

AIDS Res Hum Retroviruses, 21 (2005), pp. 922-926

http://dx.doi.org/10.1089/aid.2005.21.922 | Medline

[22.]

M. Bruguera, M. Cremades, R. Salinas, J. Costa, M. Grau, J. Sans.

Impaired response to recombinant hepatitis B vaccine in HIV-infected persons.

J Clin Gastroenterol, 14 (1992), pp. 27-30

Medline